Welcome to our dedicated page for Glycomimetics news (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on Glycomimetics stock.
The GLYC news page on Stock Titan provides an archive of disclosures and announcements related to GlycoMimetics, Inc., a late clinical-stage biotechnology company that described itself as discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases. These news items trace the company’s scientific focus on small molecule glycomimetics and its corporate evolution leading to its merger with Crescent Biopharma, Inc.
Readers can review press releases detailing clinical trial milestones for uproleselan, an investigational, first-in-class E-selectin antagonist discovered and developed by GlycoMimetics. News coverage includes topline and comprehensive results from a pivotal Phase 3 study in relapsed/refractory AML, updates on an adaptive Phase 2/3 study in newly diagnosed AML conducted by the National Cancer Institute and the Alliance for Clinical Trials in Oncology, and announcements of data presentations at major medical meetings such as the American Society of Hematology (ASH) Annual Meeting.
The archive also includes corporate updates, such as the initiation of a strategic review and corporate restructuring plan, discussions of potential business development opportunities for uproleselan and GMI-1687, and workforce reductions described as part of extending the company’s cash runway. Later news items document the acquisition agreement with Crescent Biopharma, the planned operation of the combined company under the Crescent Biopharma, Inc. name, and stockholder approval of the merger and related reverse stock split.
Because GlycoMimetics has completed a business combination and changed its name to Crescent Biopharma, Inc., the GLYC news feed serves primarily as a historical record. Investors and researchers can use this page to follow the sequence of clinical, regulatory, and strategic announcements that shaped the legacy GlycoMimetics business prior to its transition to trading under the CBIO symbol.
GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a non-qualified stock option for 200,000 shares to Dr. Edwin P. Rock, the new Senior VP and Chief Medical Officer, on September 2, 2022. This award, which has an exercise price of $0.74 per share, is part of an inducement equity package outside their equity incentive plan. Vesting occurs with 25% on September 2, 2023, followed by equal monthly installments over 36 months. GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Harout Semerjian will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on September 14, 2022, at 3:00 p.m. ET. An archived recording of the presentation will be accessible for 90 days on GlycoMimetics' website.
The company specializes in developing glycobiology-based therapies for cancers like acute myeloid leukemia (AML), aiming to create transformative treatments through its proprietary platform.
GlycoMimetics, Inc. (NASDAQ: GLYC) has appointed Edwin Rock, M.D., Ph.D., as the new Chief Medical Officer. Dr. Rock brings nearly two decades of biopharmaceutical experience, having previously served as CMO at Partner Therapeutics. He has expertise in clinical development and regulatory functions for therapies aimed at hematologic malignancies. This addition is expected to enhance GlycoMimetics' leadership as it prepares for pivotal Phase 3 data readout of its investigational drug, uproleselan, in acute myeloid leukemia (AML), which has already received Breakthrough Therapy designation from the FDA.
GlycoMimetics (Nasdaq: GLYC) received FDA clearance for its IND application to study GMI-1687 for sickle cell disease. The company is advancing its pivotal Phase 3 trial for uproleselan in relapsed/refractory acute myeloid leukemia (AML), anticipating survival data by mid-2023. As of June 30, 2022, GlycoMimetics reported cash and equivalents of $60.2 million, down from $90.3 million at year-end 2021. R&D expenses decreased to $8.0 million while G&A expenses rose to $5.5 million. A conference call is scheduled for today at 8:30 a.m. ET to discuss these developments.
GlycoMimetics, Inc. (GLYC) announced a conference call on August 3, 2022, at 8:30 a.m. ET, to discuss its second quarter financial results. Investors can participate via a registration link provided in the announcement or access a live webcast through the company’s website. GlycoMimetics is focused on developing glycobiology-based therapies for cancers like acute myeloid leukemia and inflammatory diseases. The company aims to advance its drug candidates to address significant healthcare needs.
GlycoMimetics, Inc. (NASDAQ: GLYC) will participate in the Jefferies 2022 Healthcare Conference on June 8 in New York, NY. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Roger Song, M.D. The chat will be available for 30 days on the GlycoMimetics website starting June 8 at approximately 3:30 p.m. ET. GlycoMimetics is a clinical-stage biotechnology company focused on developing glycobiology-based therapies for cancers and inflammatory diseases, aiming to create transformative treatments.
GlycoMimetics (NASDAQ: GLYC) reported its financial results for Q1 2022, with cash and equivalents at $76.5 million, down from $90.3 million at the end of 2021. The company recorded no revenue for the quarter compared to $1.1 million in Q1 2021. Research and development expenses decreased to $9.6 million, while general and administrative expenses rose to $5.1 million. The company is on track for key events in its clinical trials, including the pivotal Phase 3 trial for uproleselan in relapsed/refractory AML anticipated in mid-2023.
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call and webcast on
GlycoMimetics, Inc. (Nasdaq: GLYC) will participate in the 34th Annual Roth Conference on March 14-15 in Laguna Niguel, California. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Zegbeh Jallah. An archived recording will be available on the GlycoMimetics website starting March 15 at approximately 2:00 p.m. PST. The company focuses on developing glycobiology-based therapies for cancers and inflammatory diseases. For more information, visit www.glycomimetics.com.
GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a stock option award on March 1, 2022, for 100,000 shares to Deepak Tiwari, its new Vice President of Technical Operations. This award, approved by the compensation committee, is a non-qualified stock option granted outside the 2013 Equity Incentive Plan, complying with NASDAQ Listing Rule 5635(c)(4). The options vest 25% on March 1, 2023, with the remainder vesting monthly over three years. The exercise price is set at $1.27 per share, equal to the closing stock price on the grant date.
FAQ
What is the current stock price of Glycomimetics (GLYC)?
What is the market cap of Glycomimetics (GLYC)?
